Immunotherapy of cancer: immunospecific rejection of tumors in recipients of neuraminidase-treated tumor cells plus BCG.
Firmly established methylcholanthrene fibrosarcomas in syngeneic mice will totally disappear if the hosts are treated with living tumor cells that have been exposed to Vibrio cholerae neuraminidase in vitro. The effect is magnified by the simultanieous injection of a nonspecific immunostimulant, BCG. The rejection of the methylcholanthrene tumor is immunospecific and can be induced only with tumor cells, treated with Vibrio cholerae neuraminidase, identical in type with the growing tumor.
D000818:Animals; D000917:Antibody Formation; D005260:Female; D005354:Fibrosarcoma / Q000139:chemically induced / Q000276:immunology / Q000628:therapy*; D006084:Graft Rejection; D007114:Immunization; D008748:Methylcholanthrene; D051379:Mice; D009163:Mycobacterium bovis / Q000276:immunology*; D009368:Neoplasm Transplantation; D009374:Neoplasms, Experimental / Q000276:immunology / Q000628:therapy*; D009439:Neuraminidase / Q000032:analysis / Q000494:pharmacology*; D014181:Transplantation Immunology / Q000187:drug effects; D014184:Transplantation, Homologous; D014733:Vibrio / Q000201:enzymology
D008748:Methylcholanthrene; D009439:Neuraminidase